Sugi Predict

Sugi Predict / Compounds / SCHEMBL5332693

SCHEMBL5332693

SCHEMBL5332693

CC(C)(C)OC(=O)NCCCC[C@H](NC(=O)OCc1ccccc1)C(N)=O

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 3/20 0.65
▸ MAPT P10636 1/20 0.61
▸ KLK7 P49862 2/20 0.59
▸ KLK5 Q9Y337 2/20 0.59
▸ SYK P43405 1/20 0.57
▸ CTSL P07711 1/20 0.55
▸ FOLH1 Q04609 2/20 0.54
▸ ITGB3 P05106 1/20 0.54
▸ ITGA2B P08514 1/20 0.54
▸ SIRT1 Q96EB6 2/20 0.54
▸ SIRT3 Q9NTG7 1/20 0.53
▸ SIRT5 Q9NXA8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332690 1.00 SIRT2 (0.65) SIRT2MAPTKLK7KLK5SYK
SCHEMBL2801427 0.96 MAPT (0.66) SIRT2MAPTKLK7KLK5FOLH1
SCHEMBL2801426 0.96 MAPT (0.66) SIRT2MAPTKLK7KLK5FOLH1
SCHEMBL20653746 0.93 CTSL (0.67) SIRT2MAPTKLK7KLK5SYK
SCHEMBL5425732 0.93 MAPT (0.62) SIRT2MAPTKLK7KLK5SYK
SCHEMBL19929603 0.93 MAPT (0.62) SIRT2MAPTKLK7KLK5SYK
SCHEMBL5425736 0.93 MAPT (0.62) SIRT2MAPTKLK7KLK5SYK
SCHEMBL20209612 0.92 SYK (0.60) SIRT2MAPTKLK7KLK5SYK
SCHEMBL21460930 0.92 SYK (0.60) SIRT2MAPTKLK7KLK5SYK
SCHEMBL8124457 0.92 SIRT2 (0.60) SIRT2MAPTKLK7KLK5SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112812172-B Preparation process of lixisenatide 杭州固拓生物科技有限公司 2022-12-23 — — CN claimed
CN-121574191-A Myristoyl pentapeptide-17 and preparation method and application thereof 深圳连续制药科技有限公司 2026-02-27 — — CN disclosed
CN-118725006-A Process for preparing insoluble peptide 南京金斯瑞生物科技有限公司 2024-10-01 — — CN disclosed
CN-115925790-A Methods for synthesizing alpha 4 beta 7 peptide antagonists 领导医疗有限公司 2023-04-07 — — CN disclosed
CN-112812172-B Preparation process of lixisenatide 杭州固拓生物科技有限公司 2022-12-23 — — CN disclosed
CN-115073555-A Method for synthesizing pasireotide 中国医学科学院药物研究所 2022-09-20 — — CN disclosed
WO-2007143822-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-21 — — WO disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 — — US disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HAT1 SIRT2 52/4885MAPT 2802/4885KLK7 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.